CompuGroup Medical SE KGaA Yönetim

Yönetim kriter kontrolleri 2/4

CompuGroup Medical SE KGaA CEO'su Daniel Gotthardt, Sep2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 6.92% doğrudan sahiptir ve bu hisselerin değeri € 50.28M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 3.8 yıldır.

Anahtar bilgiler

Daniel Gotthardt

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	6.9%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Daniel Gotthardt (51 yo)

less than a year

Görev süresi

€60,000

Tazminat

Dr. Daniel Gotthardt is MD & CEO of CompuGroup Medical SE & Co. KGaA since September 1, 2024 and had been its Chief Medical Officer since 2023 until September 2024 and was its Senior Vice President from 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hannes Reichl	MD of Impatient & Social Care and Member of the Management Board	6yrs	€1.77m	0.0077% € 56.2k
Emanuele Mugnani	MD of Ambulatory Information Systems Europe & Member of Management Board	3yrs	€690.00k	0.0014% € 9.8k
Ulrich Thome	MD of Ambulatory Information Systems DACH & Member of the Management Board	less than a year	€2.40m	0.00057% € 4.1k
Daniel Gotthardt	MD & CEO	less than a year	€60.00k	6.92% € 50.3m
Daniela Hommel	MD, CFO & Member of Management Board	less than a year	Veri yok	Veri yok
Claudia Thomé	Corporate Vice President of Investor Relations	no data	Veri yok	Veri yok
Helge Weiß	Senior Vice President of Connectivity	4.8yrs	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: COP2 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philipp von Ilberg	Chairman of Supervisory Board	4.4yrs	€100.00k	Veri yok
Dierk Heimann	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Ulrike Handel	Independent Member of Supervisory Board	4.4yrs	€48.00k	Veri yok
Bettina Volkens	Member of Supervisory Board	4.4yrs	€40.00k	Veri yok
Matthias Stormer	Member of Supervisory Board	4.4yrs	€60.00k	0.0025% € 18.2k
Martin Kohrmann	Member of Supervisory Board	4.4yrs	€40.00k	0.015% € 112.4k
Ayfer Basal	Employee Representative Member of Supervisory Board	3.2yrs	€50.00k	Veri yok
Adelheid Hegemann	Employee Representative Member of Supervisory Board	3.2yrs	€40.00k	0.000070% € 508.8
Frank Betz	Employee Representative Member of Supervisory Board	3.2yrs	€50.00k	Veri yok
Stefan Weinmann	Vice Chairman of the Supervisory Board	3.2yrs	€60.00k	0.000050% € 363.4
Julia Mole	Employee Representative Member of Supervisory Board	3.8yrs	€40.00k	Veri yok
Reinhard Lyhs	Member of Supervisory Board	1.7yrs	€34.00k	0.00039% € 2.8k

3.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COP2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

CompuGroup Medical SE KGaA Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CompuGroup Medical SE & Co. KGaA Announces CEO Changes

CompuGroup Medical SE & Co. KGaA Announces Chief Executive Officer for the US Changes

CompuGroup Medical SE & Co. KGaA Appoints Daniela Hommel as Chief Financial Officer, Effective March 2024

Compugroup Medical Se & Co. KGaa Appoints Michael Rauch as CEO

CompuGroup Medical SE & Co. KGaA, Annual General Meeting, May 17, 2023

CompuGroup Medical SE & Co. KGaA Announces CEO Dirk Wössner Decides to End His Contract as of June 30, 2022

Recent updates

CompuGroup Medical SE & Co. KGaA to Report Q2, 2025 Results on Jul 31, 2025

Third quarter 2024 earnings released: EPS: €0.17 (vs €0.30 in 3Q 2023)

CompuGroup Medical SE & Co. KGaA Announces CEO Changes

Second quarter 2024 earnings released: EPS: €0.27 (vs €0.60 in 2Q 2023)

Investor sentiment deteriorates as stock falls 33%

CompuGroup Medical SE & Co. KGaA (XTRA:COP) acquired AmbulApps GmbH.

Upcoming dividend of €1.00 per share

First quarter 2024 earnings released: EPS: €0.35 (vs €0.28 in 1Q 2023)

Now 22% overvalued

CompuGroup Medical SE & Co. KGaA Proposes Dividend for the Year 2023

CompuGroup Medical SE & Co. KGaA Proposes Dividend for the Year 2023

Full year 2023 earnings released: EPS: €0.88 (vs €1.41 in FY 2022)

CompuGroup Medical SE & Co. KGaA Announces Chief Executive Officer for the US Changes

Dividend of €1.00 announced

Now 20% undervalued after recent price drop

Full year 2023 earnings released: EPS: €0.88 (vs €1.41 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

Third quarter 2023 earnings released: EPS: €0.31 (vs €0.56 in 3Q 2022)

CompuGroup Medical SE & Co. KGaA to Report Q3, 2024 Results on Nov 07, 2024

New minor risk - Share price stability

CompuGroup Medical SE & Co. KGaA Appoints Daniela Hommel as Chief Financial Officer, Effective March 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: €0.60 (vs €0.23 in 2Q 2022)

New minor risk - Share price stability

Compugroup Medical Se & Co. KGaa Appoints Michael Rauch as CEO

Upcoming dividend of €0.50 per share at 1.0% yield

CompuGroup Medical SE & Co. KGaA Confirms Revenue Guidance for 2023

First quarter 2023 earnings released: EPS: €0.28 (vs €0.35 in 1Q 2022)

Full year 2022 earnings released: EPS: €1.41 (vs €1.30 in FY 2021)

Full year 2022 earnings released: EPS: €1.41 (vs €1.30 in FY 2021)

CompuGroup Medical SE & Co. KGaA to Report Q4, 2022 Results on Feb 09, 2023

CompuGroup Medical SE & Co. KGaA to Report First Half, 2023 Results on Aug 10, 2023

CompuGroup Medical SE & Co. KGaA (XTRA:COP) acquired 20% stake in New Line Ricerche Di Mercato Societa' Benefit Spa.

CompuGroup Medical SE & Co. KGaA (XTRA:COP) agreed to acquire GHG business operations of Gotthardt Healthgroup Holding Gmbh.

CompuGroup Medical SE & Co. KGaA (XTRA:COP) agreed to acquire GHG business operations of Gotthardt Healthgroup Holding Gmbh.

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €0.56 (vs €0.54 in 3Q 2021)

CompuGroup Medical SE & Co. KGaA, Annual General Meeting, May 17, 2023

Second quarter 2022 earnings released: EPS: €0.23 (vs €0.33 in 2Q 2021)

CompuGroup Medical SE & Co. KGaA Revises Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

CompuGroup Medical SE & Co. KGaA Announces CEO Dirk Wössner Decides to End His Contract as of June 30, 2022

CompuGroup Medical SE & Co. KGaA Announces CEO Dirk Wössner Decides to End His Contract as of June 30, 2022

CompuGroup Medical SE & Co. KGaA Provides Revenue Guidance for the Year 2022

Upcoming dividend of €0.50 per share

First quarter 2022 earnings released: EPS: €0.35 (vs €0.20 in 1Q 2021)

Now 20% undervalued after recent price drop

Full year 2021 earnings released: EPS: €1.30 (vs €1.43 in FY 2020)

CompuGroup Medical SE & Co. KGaA Proposes 2021 Dividend

CompuGroup Medical SE & Co. KGaA to Report Q3, 2022 Results on Nov 03, 2022

CompuGroup Medical SE & Co. KGaA appoints ngela Mazza Teufer to the Management Board

CompuGroup Medical SE & Co. KGaA Provides Revenue Guidance for the Fiscal Year 2021 and 2022

Third quarter 2021 earnings released: EPS €0.54 (vs €0.67 in 3Q 2020)

CompuGroup Medical SE & Co. KGaA Confirms Earnings Guidance for the Year 2021

Second quarter 2021 earnings released: EPS €0.33 (vs €0.34 in 2Q 2020)

CompuGroup Medical SE & Co. KGaA Provides Earnings Guidance for the Full Year of 2021

CompuGroup Medical SE & Co. KGaA (XTRA:COP) acquired Meta IT GmbH.

CompuGroup Medical SE & Co. KGaA (XTRA:COP) acquired Visus Health It Gmbh.

Upcoming dividend of €0.50 per share

First quarter 2021 earnings released: EPS €0.20 (vs €0.26 in 1Q 2020)

CompuGroup Medical SE & Co. KGaA Confirms Earnings Guidance for the Year 2021

Full year 2020 earnings released: EPS €1.43 (vs €1.36 in FY 2019)

New 90-day low: €71.54

New 90-day high: €84.34

Third quarter 2020 earnings released: EPS €0.67

Revenue beats expectations

Third quarter 2020 earnings released: EPS €0.67

Revenue beats expectations

New 90-day high: €81.90